Scientists track rare eye disease to prepare for future treatments
NCT ID NCT01736293
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 10 times
Summary
This study follows 68 people aged 12 and older who have ABCA4 gene mutations, which can cause vision loss from diseases like Stargardt disease. Over 10 years, researchers will collect blood and skin samples and perform detailed eye exams to understand how the disease progresses. No treatment is given; the goal is to gather information for future clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help design future clinical trials for treatments targeting ABCA4-related eye diseases.
- What could go wrong
- This is an observational study with no treatment given, so it will not directly improve vision. It only tracks disease progression over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABCA4-RELATED RETINOPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can stem cells restore vision in stargardt disease? a First-in-Human trial aims to find out
- MS drug may shield eyes from damage, new study hopes to prove
- New eye scans could revolutionize how we see retinal disease
- New study aims to sharpen vision tests for the blind
- New eye injection shows promise for rare Blindness-Causing gene mutation
- Eye disease study tracks vision loss in stargardt patients